Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tralokinumab + TCS in Children and Infants with Moderate-to-severe Atopic Dermatitis
NCT06311682Phase 3Recruiting
- Sponsor
- LEO Pharma
- Start
- Jun 2024
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 3 trial of tralokinumab in atopic dermatitis (AD), sponsored by LEO Pharma. Started Jun 2024; status: recruiting.
02
Drugs
tralokinumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06311682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06311682.